Table 1. Baseline characteristics of Subcohort Patients, including stratification by iPTH categorya.
| Characteristics (%) | Baseline Serum iPTH, pg/ml |
Totalb | ||
|---|---|---|---|---|
| <300 | 300–<500 | ≥500 | ||
| n = 1,948 | n = 824 | n = 504 | n = 3,276 | |
| Demographics | ||||
| Age, yr | 62.7 (12.8) | 61.5 (12.8) | 59.7 (11.9) | 61.9 (12.7) |
| Gender | ||||
| Women | 37% | 41% | 39% | 38% |
| Men | 63% | 59% | 61% | 62% |
| Renal disease | ||||
| Glomerulonephritis | 41% | 45% | 58% | 45% |
| Diabetic nephropathy | 28% | 21% | 13% | 24% |
| Other diseases | 30% | 34% | 29% | 31% |
| Vintage, yr | 6.9 (1.5, 20.7) | 8.9 (1.7, 21.7) | 11.6 (3.1, 24.9) | 8.3 (1.6, 22.1) |
| Body mass index, kg/m2 | 21.4 (3.4) | 21.5 (3.8) | 21.2 (3.3) | 21.4 (3.5) |
| Comorbid conditions | ||||
| Cardiovascular conditions | 61% | 61% | 57% | 60% |
| Coronary artery disease | 26% | 24% | 24% | 25% |
| Atrial fibrillation | 7% | 7% | 7% | 7% |
| Other arrhythmia | 12% | 13% | 12% | 12% |
| Congestive heart failure | 9% | 7% | 6% | 8% |
| Cerebrovascular disease | 10% | 12% | 11% | 11% |
| Peripheral vascular disease | 19% | 18% | 17% | 19% |
| Aortic disease | 7% | 6% | 5% | 7% |
| Others | 14% | 14% | 15% | 14% |
| Diabetes mellitus | 36% | 29% | 18% | 31% |
| Lung disease | 7% | 6% | 9% | 7% |
| Liver disease | 14% | 14% | 15% | 14% |
| Malignancy | 4% | 6% | 6% | 5% |
| History of parathyroidectomy | 5% | 6% | 10% | 6% |
| Dementia | 3% | 4% | 3% | 3% |
| Other central nervous disease | 8% | 9% | 10% | 9% |
| Laboratory measurements and treatment variables | ||||
| Serum calciumb, mg/dl | 9.4 (0.9) | 9.4 (0.9) | 9.7 (0.9) | 9.5 (0.9) |
| <8.4 mg/dl | 10% | 10% | 8% | 10% |
| ≥8.4–≤ 10.0 mg/dl | 67% | 64% | 58% | 65% |
| >10.0 mg/dl | 23% | 26% | 34% | 25% |
| Serum phosphorus, mg/dl | 5.3 (1.3) | 5.8 (1.4) | 6.1 (1.5) | 5.5 (1.4) |
| <3.5 mg/dl | 6% | 4% | 2% | 5% |
| ≥3.5–≤ 6.0 mg/dl | 69% | 58% | 48% | 63% |
| >6.0 mg/dl | 25% | 38% | 50% | 32% |
| Serum iPTH, pg/ml | 206 (91, 278) | 371 (312, 464) | 692 (524, 1183) | 265 (124, 611) |
| VDRA | ||||
| Intravenous | 46% | 45% | 66% | 49% |
| Oral | 34% | 27% | 12% | 29% |
| None | 20% | 28% | 22% | 23% |
| Phosphate binder | ||||
| Both | 23% | 23% | 24% | 23% |
| Calcium-based | 48% | 42% | 30% | 44% |
| Not calcium-based | 14% | 20% | 34% | 18% |
| None | 15% | 15% | 13% | 15% |
| Dialysate calcium | ||||
| <3 mg/dl | 52% | 51% | 52% | 52% |
| ≥3 mg/dl | 48% | 49% | 48% | 48% |
| Kt/V | 1.41 (0.3) | 1.42 (0.3) | 1.45 (0.3) | 1.42 (0.3) |
| Hemoglobin, g/dl | 10.5 (1.2) | 10.5 (1.1) | 10.5 (1.2) | 10.5 (1.2) |
| Serum albumin, g/dl | 3.74 (0.4) | 3.77 (0.4) | 3.78 (0.3) | 3.75 (0.4) |
| Serum creatinine, mg/dl | 11.0 (2.9) | 11.3 (2.9) | 11.8 (2.8) | 11.2 (2.9) |
| Serum cholesterol, mg/dl | 155 (36) | 154 (34) | 154 (33) | 154 (35) |
| Serum iron, μg/dl | 59 (33, 95) | 57 (32, 93) | 58 (31, 92) | 58 (33, 94) |
| Serum ferritin, ng/dl | 124 (22, 394) | 119 (18, 405) | 91 (18, 316) | 118 (20, 391) |
| Serum CRP, mg/L | 1.1 (0.3, 10.2) | 1.1 (0.3, 11) | 1.0 (0.3, 8.4) | 1.1 (0.3, 10) |
aMean (SD) are shown for normally distributed data; otherwise, median (p10, p90) are shown for non-normally distributed data.
bCorrected for albumin concentration using modified Payne method.